查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1864579

Duchenne氏肌肉失养症治疗药物市场（依药物类别、通路、最终用户、剂型及给药途径划分）－2025-2032年全球预测

Duchenne Muscular Dystrophy Drugs Market by Drug Class, Distribution Channel, End User, Form, Route Of Administration - Global Forecast 2025-2032
出版日期: | 出版商: 360iResearch | 英文 190 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

预计到 2032 年，Duchenne氏肌肉失养症治疗市场将成长至 33.6 亿美元，复合年增长率为 8.87%。

关键市场统计数据
基准年 2024 17亿美元
预计年份：2025年 18.5亿美元
预测年份 2032 33.6亿美元
复合年增长率 (%) 8.87%

透过摘要整个生态系中的科学进展、临床重点和相关人员的需求，为Duchenne氏肌肉失养症的治疗策略奠定基础。

Duchenne氏肌肉失养症仍然是临床和商业性最复杂的罕见疾病领域之一，其特征是进行性性肌肉退化、给看护者带来沉重负担，以及对疾病修正治疗的持续需求。过去十年来的科学进步已将该领域从对症治疗转变为靶向分子干预，从而构建了一个紧密交织的治疗方法、监管合作和支付方参与策略的生态系统。临床医生、患者家属和政策制定者越来越需要证据，不仅要证明生物活性，还要证明其具有实际的功能性疗效、长期安全性以及永续的用药模式。

在此背景下，产业相关人员面临着一个需要整合药物发现、临床开发、生产和商业化等各环节的挑战。新兴治疗方法，例如外显子跳跃疗法、基于腺相关病毒载体的基因替代疗法以及改良型皮质类固醇疗法，各自拥有独特的科学原理、监管考虑和运作模式。此外，随着精准医疗技术不断改进病患选择和疗效评估方法，相关人员必须在创新与可扩展的生产和分销模式之间取得平衡。本执行摘要整合了上述各方面内容，旨在为战略决策提供背景信息，并重点介绍加速产品研发管线转化为患者获益的潜在途径。

前所未有的科学、製造和价值导向医疗保健转型正在重塑Duchenne氏肌肉失养症治疗的临床开发、分销和报销策略。

过去几年，Duchenne氏肌肉失养症的治疗研发和实施方式发生了变革性变化，影响着临床实验设计、药物生产和长期照护模式。科学创新使得针对该疾病潜在基因缺陷的标靶化更加精准，推动了治疗模式从「一刀切」转向针对特定治疗方法的研发路径，这需要个性化的监管和生产策略。同时，测量科学也日趋成熟，新型功能性终点、数位生物标记和患者报告结局被整合到关键研发项目中，以便在规模更小、更多样化的人群中捕捉具有临床意义的疗效。

在营运层面，该产业正经历同步的变革。依赖腺相关病毒（AAV）载体的基因疗法正推动对载体生产能力、品管和长期安全监测系统的迫切投资。血清型选择，例如AAV6或AAV9，会影响分布动力学、组织亲和性和生产复杂性，进而影响临床策略和商业性可行性。同时，外显子跳跃药物和优化的皮质类固醇方案也在不断改进，以在给药、监测和目标患者群体方面展现差异化特性。这些技术和流程的变革正在促进生物技术公司、契约製造製造商和专科药房之间的新合作，同时也促使支付方和医疗系统考虑采用基于绩效的报销和风险分担模式，以应对高昂的前期成本和不确定的长期疗效。

鑑于这些变化，行业领导者必须在研发早期整合科学、製造和商业计划，以降低后期专案的风险，并协调相关人员对真实世界证据收集和患者获取的期望。

评估计画于 2025 年进行的美国关税调整对Duchenne氏肌肉失养症治疗药物的供应链、製造地选择和商业性准入策略的影响。

贸易政策变化和关税考量已成为生物製药供应链策略规划的重要因素，而美国提案的2025年关税调整方案，则为Duchenne氏肌肉失养症治疗领域的企业带来了新的变数。生物製药生产的原料（例如质体DNA、特殊试剂、一次性使用系统和腺相关病毒（AAV）生产原料）在其生产週期中往往需要多次跨境运输。因此，关税和海关重新分类可能会增加到岸成本、延长前置作业时间，并促使奖励重新评估供应商所在地。

为此，各组织正在重新评估其短期筹资策略，并寻求多元化以分散风险。一些公司正在加快对本地生产能力的投资，并签订长期供应协议，以确保价格可预测并优先分配产能。这些战略选择会产生连锁反应。虽然回流或地域多角化可以降低进口关税风险，但在严格的法规结构下对新的製造地进行认证可能需要大量的资金投入和时间。此外，不断上涨的进口成本将影响与支付方和政府采购机构的价格谈判，从而增加企业证明其临床疗效和成本效益的持续性压力。

重点，跨境成本的上升将提升供应链透明度和库存优化的重要性，促使企业实施更精细的需求预测、需求感知和缓衝库存策略。监管和海关合规团队应儘早参与计划规划阶段，以避免因意外的商品分类变更而产生关税。总而言之，虽然关税只是众多商业性变数之一，但其累积影响会影响生产策略、合作伙伴选择以及将先进的Duchenne氏肌肉失养症疗法引入不同市场的经济效益。

将药物类别、通路、终端用户环境、剂型和给药途径整合到以细分市场主导的策略中，从而得出可操作的商业性和临床结论。

从多个临床和商业性角度考虑治疗方法时，细分市场分析揭示了清晰的策略意义。依药物类别划分，外显子跳跃疗法、基因疗法和类固醇疗法各自需要独特的临床开发模式和证据包。在基因疗法领域，基于腺相关病毒（AAV）和非病毒疗法之间的差异会影响载体选择、免疫抗原性管理和生产路线决策。此外，深入研究血清型选择，例如AAV血清型6或血清型9，决定了组织标靶化、给药策略和生产规模的复杂性。考虑通路，可以发现医院药房、线上药房和零售药房之间存在不同的物流和合规要求。每种管道在低温运输、报销和患者支援需求方面都面临着独特的挑战。从最终使用者的观点来看，居家医疗环境的需求与医院或专科诊所环境的需求有显着差异，这会影响训练、监测频率以及输液相关事件的紧急应变准备。剂型和给药途径对药物的接受度和患者依从性至关重要，胶囊和口服片剂与注射剂或静脉注射相比，能为患者带来不同的用药体验。此外，肌肉注射、静脉注射和口服给药途径各自都有其独特的临床监测和给药基础设施需求。

整合这些细分维度表明，产品组合设计不能孤立地进行。例如，用于医院静脉注射的基于AAV9的基因替代药物候选产品的商业化投资，与透过零售药局分销供家庭使用的口服类固醇疗法的商业化投资截然不同。因此，上市计划必须从研发初期就将临床设计与下游分销、支付方参与和病患支援服务结合。这种整合观点能够提供反映实际应用情况的客製化价值提案，从而降低准入门槛，并为监管机构和支付方提供强有力的证据支持。

评估美洲、欧洲、中东和非洲以及亚太地区在监管、报销和营运方面的区域差异，以帮助制定分阶段的市场进入和准入策略。

区域趋势正在影响Duchenne氏肌肉失养症治疗药物的采纳和准入途径，每个地区都有其独特的监管、报销和运作方面的考虑。美洲拥有成熟的专科治疗中心网络、完善的罕见疾病临床试验基础设施，以及重视卫生技术评估和基于价值的合约的支付方，这些因素共同影响着药物的核准顺序和商业性化上市。在欧洲、中东和非洲地区，监管途径各不相同，报销决策往往涉及各国监管机构，而他们对疗效比较证据的要求也存在差异，因此需要儘早协调不同的证据策略和建立区域特定的卫生经济学模型。亚太地区拥有快速发展的临床研究能力、日益增长的产业伙伴关係意愿以及多元化的製造生态系统。然而，市场进入策略必须考虑到不同的监管要求、价格控制和患者准入计划。

因此，区域策略应优先考虑灵活的监管路径、分阶段的市场准入计划以及能够充分利用当地临床专长和分销网络的伙伴关係。跨境物流规划对于需要低温运输或即时给药的先进医疗技术尤其重要，而区域製造地有助于患者儘早获得治疗，同时降低关税和进口风险。最终，了解这些区域差异将有助于与相关人员进行更精准的合作，并透过使产品交付模式与当地医疗服务体系相契合，提高早期推广应用的可能性。

分析企业在载体设计、生产规模化和相关人员参与方面的策略将如何决定Duchenne氏肌肉失养症治疗药物的临床开发进展和商业化准备。

公司层面的趋势对Duchenne氏肌肉失养症疗法的创新速度和方向起着至关重要的作用。专注于外显子跳跃和小分子疗法的生物技术公司不断改进有效载荷化学、递送优化和患者选择标准，以实现临床差异化。致力于基因替代疗法的机构则专注于载体设计、血清型选择和可扩展的GMP生产，以减少批次间差异并支持稳定的临床供应。在整个产业中，策略联盟，例如研究合作、授权协议和生产伙伴关係，经常被用于弥补产能缺口并加快临床试验进程。

投资者和公司的优先事项也在转变。除了临床里程碑之外，营运执行、后期安全性监测计画和商业化准备也日益受到重视。拥有整合临床开发、生产规模化和与支付方合作策略的公司往往能更有效地应对后期关键节点。此外，病患权益组织和临床医师网路发挥强大的协调作用，影响临床实验试验的招募、终点选择和核准后证据的产生。因此，投资于透明的相关人员参与和患者支持基础设施的公司可以提高临床实验参与率和长期应用率。最后，积极应对生产能力、供应链韧性和监管路径的组织更有能力将研发成果转化为患者可获得的治疗方法。

应采取综合方法，将早期生产规划、适应性证据产生、供应多样化和以患者为中心的服务联繫起来，以降低开发风险并加快获取途径。

行业领导者应采取协调一致、风险平衡的方法，将科学策略与生产和市场进入计划相结合，以加速实现永续的患者获益。首先，将生产的考量纳入早期临床设计决策，可降低后期供应受限的可能性，并有助于与监管机构就可比性和长期追踪进行清晰的讨论。其次，企业应优先考虑适应性证据的生成，将可靠的临床终点与可操作的真实世界数据收集相结合，以支持产品迭代改进，同时满足监管机构和支付方的需求。第三，供应商网路多元化和探索区域製造地可以降低关税和跨境风险，而与经验丰富的生物製药生产商签订长期产能协议则可以确保关键原材料的供应。

此外，以患者为中心的服务和数位化监测平台的投资将有助于提高患者依从性，获取有意义的治疗结果，并加强与支付方的价值评估。儘早与患者权益倡导组织进行透明的沟通，将加快患者招募速度，并使研发项目与对家庭至关重要的日常生活改善相契合。最后，领导者应寻求与研究机构、契约製造和专业分销管道建立策略伙伴关係，以弥补产能缺口，并加快扩大患者群体的可及性。共同实施这些倡议，将建构一个更具韧性、以实证医学为基础的方法，为Duchenne氏肌肉失养症患者带来变革性的治疗方案。

请描述您的混合方法分析方法，该方法结合了专家访谈、监管审查和供应链映射，以检验策略见解，而无需依赖定量市场规模。

本执行摘要的研究采用了混合方法，旨在全面了解Duchenne氏肌肉失养症治疗研发相关的科学、营运和商业性方面的问题。主要研究包括对临床专家、生产专家、支付方顾问和患者权益组织代表进行结构化访谈，以检验治疗方法的具体挑战和证据预期。次要研究整合了同侪审查文献、监管指导文件、临床试验註册资讯和上市公司揭露资料，以梳理不断发展的技术趋势、安全性考量和试验终点。交叉检验过程将访谈结果与文献证据进行比较，以确保结果的一致性并减少偏差。

我们的分析方法着重于定性三角验证和基于情境的风险评估，而非定量市场规模估算。我们特别关註生物製药生产的供应链图谱绘製，以及评估血清型选择与基因疗法临床策略之间的相互作用。在适用情况下，我们参考监管先例和已发表的长期追踪框架，并进行了上市后证据需求评估。本研究的限制包括临床数据的流动性和政策环境的变化。因此，我们建议读者结合新的试验结果和监管决策来解读我们的研究结果。

整合策略重点和营运挑战，这将决定Duchenne氏肌肉失养症治疗的科学进步能否转化为持续的临床益处和广泛的患者群体。

总之，Duchenne氏肌肉失养症的治疗格局正处于一个关键的转折点，科学创新、生产现实和支付方的期望在此交汇，共同决定哪些治疗方法能够惠及患者以及这些疗法在临床实践中的应用方式。外显子跳跃、基因治疗载体和优化类固醇疗法的进展具有改变疾病进程的真正潜力，但要实现这一潜力，需要研发、生产和商业化团队之间的协调规划。对可扩展生产进行策略性投资、儘早与监管机构和支付方开展合作、制定全面的真实世界证据计划以及建立健全的患者支持模式，将在将临床潜力转化为永续的患者可及性方面发挥关键作用。

在相关人员应对关税政策、区域监管差异和不断变化的证据标准之际，灵活性和积极的相关人员协作将使那些能够迅速将科学突破转化为永续的临床和商业性成果的机构脱颖而出。未来的道路需要整合执行、与患者群体进行透明沟通，以及製定适应性强的证据策略，优先考虑可衡量的患者获益，同时兼顾治疗可及性的长期永续性。

目录

第一章：序言

第二章调查方法

第三章执行摘要

第四章 市场概览

第五章 市场洞察

  • 扩大以腺相关病毒载体（AAV）为基础的Dystrophin基因治疗在儿科患者的试验
  • 加速针对第51号外显子突变的CRISPR-Cas9基因组编辑计划
  • 监管机构对Duchenne氏肌肉失养症药物核准替代终点的接受度不断提高
  • 生技公司与病患权益组织在临床试验设计上进行新的合作
  • 针对个体肌肉Dystrophin基因突变开发多外显子跳跃疗法
  • 人们对结合抗发炎药物和肌肉再生药物的联合治疗越来越感兴趣。
  • 推出用于DMD试验中功能性结果远端监测的数位健康平台
  • 新一代腺相关病毒载体的进步提高了肌肉组织亲和性和安全性。
  • 增加对干细胞疗法的投资，以恢復产生肌肉营养不良蛋白的肌肉细胞。
  • 随着多国註册机构的出现，有关 DMD 治疗结果的真实世界证据正在被收集。

第六章：美国关税的累积影响，2025年

第七章：人工智慧的累积影响，2025年

第八章Duchenne氏肌肉失养症治疗药物市场（依药物类别划分）

  • 外显子跳跃
  • 基因治疗
    • 基于AAV的
      • 血清型 6
      • 血清型 9
    • 非病毒性
  • 类固醇疗法

第九章Duchenne氏肌肉失养症治疗市场（依通路划分）

  • 医院药房
  • 网路药房
  • 零售药房

第十章Duchenne氏肌肉失养症治疗市场（依最终用户划分）

  • 家庭医疗保健环境
  • 医院
  • 专科诊所

第十一章Duchenne氏肌肉失养症治疗市场（按类型划分）

  • 胶囊
  • 注射
  • 口服锭剂

第十二章Duchenne氏肌肉失养症治疗药物市场（依给药途径划分）

  • 肌肉内注射
  • 静脉注射
  • 口服

第十三章Duchenne氏肌肉失养症治疗市场（按地区划分）

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 欧洲、中东和非洲
    • 欧洲
    • 中东
    • 非洲
  • 亚太地区

第十四章Duchenne氏肌肉失养症治疗市场（按组别划分）

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第十五章 各国Duchenne氏肌肉失养症症治疗市场

  • 美国
  • 加拿大
  • 墨西哥
  • 巴西
  • 英国
  • 德国
  • 法国
  • 俄罗斯
  • 义大利
  • 西班牙
  • 中国
  • 印度
  • 日本
  • 澳洲
  • 韩国

第十六章 竞争格局

  • 2024年市占率分析
  • FPNV定位矩阵，2024
  • 竞争分析
    • Sarepta Therapeutics, Inc.
    • Pfizer Inc.
    • BioMarin Pharmaceutical Inc.
    • Roche Holding AG
    • Bayer Aktiengesellschaft
    • Solid Biosciences, Inc.
    • Cytokinetics, Inc.
    • NS Pharma, Inc.
Product Code: MRR-5E3B35529469

The Duchenne Muscular Dystrophy Drugs Market is projected to grow by USD 3.36 billion at a CAGR of 8.87% by 2032.

KEY MARKET STATISTICS
Base Year [2024] USD 1.70 billion
Estimated Year [2025] USD 1.85 billion
Forecast Year [2032] USD 3.36 billion
CAGR (%) 8.87%

Setting the stage for Duchenne muscular dystrophy therapeutic strategies by summarizing scientific progress, clinical priorities, and stakeholder imperatives across the ecosystem

Duchenne muscular dystrophy remains one of the most clinically and commercially complex rare disease areas, characterized by progressive muscle degeneration, substantial caregiver burden, and a persistent need for disease-modifying therapies. Scientific advances over the past decade have shifted the field beyond symptomatic care toward targeted molecular interventions, creating a dense ecosystem of therapeutic modalities, regulatory interactions, and payer engagement strategies. Clinicians, families, and policymakers increasingly demand evidence not only of biological activity, but of meaningful functional benefit, long-term safety, and sustainable access models.

Against this backdrop, industry participants face a landscape that requires integrated thinking across discovery, clinical development, manufacturing, and commercialization. Emerging modalities such as exon skipping, gene replacement strategies using AAV vectors, and refined corticosteroid regimens each carry distinct scientific rationales, regulatory considerations, and operational footprints. Moreover, as precision medicine techniques refine patient selection and outcome measurement, stakeholders must balance innovation with scalable manufacturing and distribution approaches. This executive summary synthesizes those dimensions, providing context for strategic decisions and highlighting levers that can accelerate translation from pipeline to patient impact.

Unprecedented scientific, manufacturing, and value-based care shifts are reshaping clinical development, distribution, and reimbursement strategies for Duchenne therapeutics

The past several years have produced transformative shifts that are redefining how Duchenne therapies are developed and delivered, with consequences for trial design, manufacturing, and long-term care models. Scientific innovations have enabled more precise targeting of the genetic defects underpinning the disease, prompting a move away from one-size-fits-all approaches toward modality-specific development paths that require bespoke regulatory and manufacturing strategies. Concurrently, measurement science has matured: novel functional endpoints, digital biomarkers, and patient-reported outcomes are being integrated into pivotal development programs to capture clinically meaningful benefit in smaller, more heterogeneous populations.

Operationally, the industry is experiencing a parallel transition. Gene-based therapeutics reliant on AAV vectors are driving urgent investments in vector manufacturing capacity, quality control, and long-term safety monitoring systems. The choice of serotype, such as AAV6 or AAV9, now influences distribution kinetics, tissue tropism, and manufacturing complexity, which in turn affects clinical strategy and commercial viability. At the same time, exon skipping agents and optimized corticosteroid approaches continue to be refined, offering differentiated profiles in terms of administration, monitoring, and patient populations. These technological and procedural shifts are fostering new partnerships between biotech innovators, contract manufacturers, and specialty pharmacies, while also prompting payers and health systems to explore outcomes-based reimbursement and risk-sharing models to manage high upfront costs with uncertain long-term benefit trajectories.

Taken together, these shifts demand that industry leaders integrate scientific, manufacturing, and commercial planning earlier in development to de-risk late-stage programs and align stakeholder expectations around real-world evidence collection and patient access.

Assessing how anticipated United States tariff adjustments in 2025 may influence supply chains, manufacturing localization choices, and commercial access strategies for Duchenne therapies

Trade policy changes and tariff considerations have become material factors in strategic planning for biopharma supply chains, and proposed tariff adjustments in the United States during 2025 represent an additional variable for companies operating in the Duchenne therapeutic space. Raw materials for biologics production, including plasmid DNA, specialized reagents, single-use systems, and AAV manufacturing inputs, often cross borders multiple times during the manufacturing lifecycle. Consequently, tariffs or customs reclassifications can increase landed costs, extend lead times, and create incentives to re-evaluate supplier footprints.

In response, organizations are reassessing near-term sourcing strategies and exploring diversification to mitigate exposure. Some are accelerating investments in localized production capacity or entering long-term supply agreements to lock predictable pricing and prioritize capacity allocation. These strategic choices have knock-on effects: onshoring or regionalizing production can reduce exposure to import duties but may require significant capital expenditure and time to qualify new manufacturing sites under stringent regulatory frameworks. Moreover, increased import costs can influence pricing discussions with payers and government purchasers, intensifying pressure to demonstrate durable clinical benefit and cost-effectiveness.

Importantly, higher cross-border costs also elevate the value of supply chain transparency and inventory optimization, prompting firms to adopt more sophisticated forecasting, demand-sensing, and buffer stock policies. Regulatory and customs compliance teams will need to engage earlier in project planning to avoid unexpected classification changes that trigger tariffs. Overall, while tariffs are only one of many commercial variables, their cumulative impact can shape manufacturing strategies, partner selection, and the economics of bringing advanced Duchenne therapies to diverse markets.

Deriving practical commercial and clinical implications by integrating drug class, distribution channel, end-user context, form factors, and administration routes into segmentation-driven strategy

Segmentation analysis reveals distinct strategic implications when therapies are examined through multiple clinical and commercial lenses. When viewed by drug class, exon skipping agents, gene therapy approaches, and steroid regimens each demand unique clinical development paradigms and evidence packages; within gene therapy, the division between AAV-based and nonviral modalities affects vector selection, immunogenicity management, and manufacturing pathway decisions, while further consideration of AAV serotype choices such as serotype 6 and serotype 9 drives tissue targeting, dosing strategy, and production scale complexity. Examining distribution channels highlights the varying logistical and compliance requirements across hospital pharmacies, online pharmacies, and retail pharmacies, with each channel posing different cold-chain, reimbursement capture, and patient support needs. From an end-user perspective, the demands of home healthcare settings contrast sharply with hospital and specialty clinic environments, affecting training, monitoring cadence, and emergency preparedness for infusion-related events. Form and route of administration are central to adoption and patient adherence; capsules and oral tablets enable different patient journeys than injectables or intravenous administrations, and intramuscular, intravenous, and oral routes each carry specific clinical monitoring and administration infrastructure requirements.

Synthesizing these segmentation axes underscores that portfolio design cannot be siloed. For example, a gene replacement candidate using AAV9 intended for hospital-based intravenous administration will require different commercialization investments than an orally administered steroid therapy distributed through retail pharmacies for home use. Therefore, go-to-market planning must align clinical designs with downstream distribution, payer engagement, and patient-support services early in development. This integrated perspective enables tailored value propositions that reflect real-world use cases, reduce adoption friction, and support compelling evidence generation strategies for regulators and payers alike.

Evaluating regional regulatory, reimbursement, and operational nuances across the Americas, Europe Middle East & Africa, and Asia-Pacific to inform phased market entry and access strategies

Regional dynamics will shape the deployment and access pathways for Duchenne therapies, and each geography presents distinct regulatory, reimbursement, and operational considerations. In the Americas, there is a mature network of specialized centers, established rare disease clinical trial infrastructure, and payers that emphasize health technology assessment and value-based arrangements, which collectively influence the sequencing of approvals and commercial launches. In Europe, Middle East & Africa, regulatory pathways are diverse and reimbursement decision-making frequently involves national authorities with differing expectations for comparative effectiveness evidence, necessitating early alignment on heterogenous evidence strategies and localized health economic modeling. The Asia-Pacific region presents rapidly evolving clinical research capacity, a growing appetite for industry partnerships, and varied manufacturing ecosystems; however, market access strategies must account for divergent regulatory requirements, pricing controls, and patient access programs.

Consequently, regional strategies should prioritize flexible regulatory pathways, phased market entry plans, and partnerships that leverage local clinical expertise and distribution networks. Cross-border logistical planning is particularly important for advanced therapies with cold-chain or clinic-based administration needs, and regional manufacturing hubs can mitigate tariff or import vulnerabilities while supporting faster patient access. Ultimately, understanding these regional nuances enables more precise stakeholder engagement and increases the likelihood of early adoption by aligning product delivery models with local healthcare delivery architectures.

Analyzing how company strategies around vector engineering, manufacturing scale-up, and stakeholder engagement determine clinical progression and commercial readiness in Duchenne therapeutics

Company-level dynamics are pivotal in shaping the pace and direction of innovation in Duchenne therapeutics. Biotech firms focusing on exon skipping and small-molecule approaches continue to refine payload chemistry, delivery optimization, and patient-selection criteria to enhance clinical differentiation. Organizations pursuing gene replacement therapies are concentrating on vector engineering, serotype selection, and scalable GMP manufacturing to reduce batch-to-batch variability and support consistent clinical supply. Across the industry, strategic alliances-whether through research collaborations, licensing deals, or manufacturing partnerships-are frequently used to bridge capability gaps and accelerate time to clinic.

Investor and corporate priorities are also evolving: there is greater emphasis on operational execution, late-stage safety monitoring plans, and commercial readiness in parallel with clinical milestones. Companies with integrated strategies that align clinical development with manufacturing scale-up and payer engagement tend to navigate late-stage inflection points more effectively. In addition, patient advocacy groups and clinician networks are powerful conveners, influencing trial recruitment, endpoint selection, and post-approval evidence generation, so companies that invest in transparent stakeholder engagement and patient support infrastructure can strengthen both trial enrollment and long-term uptake. Finally, organizations that proactively address manufacturing capacity, supply chain resilience, and regulatory pathways are better positioned to translate R&D successes into accessible therapies for patients.

Adopt integrated actions linking early manufacturing planning, adaptive evidence generation, supply diversification, and patient-centered services to de-risk development and accelerate access

Industry leaders should adopt a coordinated, risk-balanced approach that links scientific strategy with manufacturing and market access planning to accelerate sustainable patient impact. Firstly, integrating manufacturing considerations into early clinical design decisions reduces the likelihood of late-stage supply constraints and enables clearer discussions with regulators about comparability and long-term follow-up. Secondly, firms should prioritize adaptive evidence generation that combines robust clinical endpoints with pragmatic real-world data collection to meet the needs of regulators and payers while supporting iterative product improvements. Thirdly, diversifying supplier networks and exploring regional manufacturing hubs can mitigate tariff and cross-border risks, while long-term capacity agreements with experienced biologics manufacturers can secure critical inputs.

Furthermore, investment in patient-centric services and digital monitoring platforms can improve adherence, capture meaningful outcomes, and strengthen value discussions with payers. Engaging patient advocacy groups early and transparently augments recruitment and aligns development programs with daily life improvements that matter to families. Lastly, leaders should pursue strategic partnerships-spanning research institutions, contract manufacturers, and specialty distribution channels-to fill capability gaps and accelerate time to broader access. Implementing these actions in concert will create a more resilient, evidence-driven approach to bringing transformative Duchenne therapies to patients.

Describe the mixed-methods analytical approach combining expert interviews, regulatory reviews, and supply chain mapping to validate strategic insights without relying on numerical market sizing

The research underpinning this executive synthesis utilized a mixed-methods approach to capture scientific, operational, and commercial dimensions relevant to Duchenne therapeutic development. Primary research included structured interviews with clinical experts, manufacturing specialists, payer advisors, and patient advocacy representatives to validate modality-specific challenges and evidence expectations. Secondary research synthesized peer-reviewed literature, regulatory guidance documents, clinical trial registries, and publicly disclosed corporate filings to map technology trajectories, safety considerations, and trial endpoint evolution. Cross-validation steps compared insights from interviews with documentary evidence to ensure consistency and reduce bias.

Analytical methods emphasized qualitative triangulation and scenario-based risk assessment rather than quantitative market sizing. Special attention was given to supply chain mapping for biologics manufacturing and to evaluating the interplay between serotype selection and clinical strategy for gene therapies. Wherever applicable, regulatory precedent and published long-term follow-up frameworks informed the assessment of post-market evidence needs. Limitations include the evolving nature of clinical data and policy environments; consequently, readers are advised to consider these findings alongside emerging trial results and regulatory decisions as they become available.

Synthesize strategic priorities and execution imperatives that will determine whether scientific advances in Duchenne therapies translate into durable clinical benefit and broad patient access

In conclusion, the Duchenne therapeutic landscape is at a pivotal juncture where scientific innovation, manufacturing realities, and payer expectations converge to shape which therapies reach patients and how they are adopted in practice. Progress in exon skipping, gene therapy vectors, and optimized steroid regimens offers real potential to alter disease trajectories, but realizing that potential depends on synchronized planning across R&D, manufacturing, and commercial teams. Strategic investments in scalable manufacturing, early engagement with regulators and payers, comprehensive real-world evidence plans, and robust patient support models will be decisive in translating clinical promise into sustainable patient access.

As stakeholders navigate tariff policies, regional regulatory heterogeneity, and evolving evidence standards, flexibility and proactive stakeholder alignment will differentiate organizations that can rapidly convert scientific breakthroughs into durable clinical and commercial outcomes. The path forward requires integrated execution, transparent engagement with patient communities, and adaptive evidence strategies that prioritize measured benefit for patients while addressing the long-term sustainability of therapeutic access.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Expansion of AAV-based micro-dystrophin gene therapy trials in pediatric patients
  • 5.2. Acceleration of CRISPR-Cas9 genome editing programs targeting exon 51 mutations
  • 5.3. Increasing regulatory acceptance of surrogate endpoints in Duchenne drug approvals
  • 5.4. Emerging collaboration between biotech innovators and patient advocacy groups for trial design
  • 5.5. Development of multiplex exon-skipping therapies customized to individual dystrophin gene mutations
  • 5.6. Growing focus on combination regimens integrating anti-inflammatory and muscle regeneration agents
  • 5.7. Adoption of digital health platforms for remote monitoring of functional outcomes in DMD trials
  • 5.8. Advancements in next-generation AAV vectors for enhanced muscle tissue tropism and safety
  • 5.9. Rising investments in stem cell therapy approaches to restore dystrophin-producing myocytes
  • 5.10. Emergence of multi-country registries capturing real-world evidence on DMD treatment outcomes

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Duchenne Muscular Dystrophy Drugs Market, by Drug Class

  • 8.1. Exon Skipping
  • 8.2. Gene Therapy
    • 8.2.1. Aav Based
      • 8.2.1.1. Serotype 6
      • 8.2.1.2. Serotype 9
    • 8.2.2. Nonviral
  • 8.3. Steroid Therapy

9. Duchenne Muscular Dystrophy Drugs Market, by Distribution Channel

  • 9.1. Hospital Pharmacies
  • 9.2. Online Pharmacies
  • 9.3. Retail Pharmacies

10. Duchenne Muscular Dystrophy Drugs Market, by End User

  • 10.1. Home Healthcare Settings
  • 10.2. Hospitals
  • 10.3. Specialty Clinics

11. Duchenne Muscular Dystrophy Drugs Market, by Form

  • 11.1. Capsule
  • 11.2. Injectable
  • 11.3. Oral Tablet

12. Duchenne Muscular Dystrophy Drugs Market, by Route Of Administration

  • 12.1. Intramuscular
  • 12.2. Intravenous
  • 12.3. Oral

13. Duchenne Muscular Dystrophy Drugs Market, by Region

  • 13.1. Americas
    • 13.1.1. North America
    • 13.1.2. Latin America
  • 13.2. Europe, Middle East & Africa
    • 13.2.1. Europe
    • 13.2.2. Middle East
    • 13.2.3. Africa
  • 13.3. Asia-Pacific

14. Duchenne Muscular Dystrophy Drugs Market, by Group

  • 14.1. ASEAN
  • 14.2. GCC
  • 14.3. European Union
  • 14.4. BRICS
  • 14.5. G7
  • 14.6. NATO

15. Duchenne Muscular Dystrophy Drugs Market, by Country

  • 15.1. United States
  • 15.2. Canada
  • 15.3. Mexico
  • 15.4. Brazil
  • 15.5. United Kingdom
  • 15.6. Germany
  • 15.7. France
  • 15.8. Russia
  • 15.9. Italy
  • 15.10. Spain
  • 15.11. China
  • 15.12. India
  • 15.13. Japan
  • 15.14. Australia
  • 15.15. South Korea

16. Competitive Landscape

  • 16.1. Market Share Analysis, 2024
  • 16.2. FPNV Positioning Matrix, 2024
  • 16.3. Competitive Analysis
    • 16.3.1. Sarepta Therapeutics, Inc.
    • 16.3.2. Pfizer Inc.
    • 16.3.3. BioMarin Pharmaceutical Inc.
    • 16.3.4. Roche Holding AG
    • 16.3.5. Bayer Aktiengesellschaft
    • 16.3.6. Solid Biosciences, Inc.
    • 16.3.7. Cytokinetics, Inc.
    • 16.3.8. NS Pharma, Inc.

LIST OF FIGURES

  • FIGURE 1. GLOBAL DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY DRUG CLASS, 2024 VS 2032 (%)
  • FIGURE 3. GLOBAL DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY DRUG CLASS, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 4. GLOBAL DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2032 (%)
  • FIGURE 5. GLOBAL DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY END USER, 2024 VS 2032 (%)
  • FIGURE 7. GLOBAL DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY END USER, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY FORM, 2024 VS 2032 (%)
  • FIGURE 9. GLOBAL DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY FORM, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2032 (%)
  • FIGURE 11. GLOBAL DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY REGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 13. AMERICAS DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 14. NORTH AMERICA DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 15. LATIN AMERICA DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 16. EUROPE, MIDDLE EAST & AFRICA DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 17. EUROPE DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 18. MIDDLE EAST DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 19. AFRICA DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 20. ASIA-PACIFIC DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 21. GLOBAL DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY GROUP, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 22. ASEAN DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 23. GCC DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 24. EUROPEAN UNION DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 25. BRICS DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 26. G7 DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 27. NATO DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 28. GLOBAL DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 29. DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SHARE, BY KEY PLAYER, 2024
  • FIGURE 30. DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET, FPNV POSITIONING MATRIX, 2024

LIST OF TABLES

  • TABLE 1. DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
  • TABLE 3. GLOBAL DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, 2018-2024 (USD MILLION)
  • TABLE 4. GLOBAL DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, 2025-2032 (USD MILLION)
  • TABLE 5. GLOBAL DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
  • TABLE 6. GLOBAL DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY DRUG CLASS, 2025-2032 (USD MILLION)
  • TABLE 7. GLOBAL DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY EXON SKIPPING, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 8. GLOBAL DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY EXON SKIPPING, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 9. GLOBAL DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY EXON SKIPPING, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 10. GLOBAL DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY EXON SKIPPING, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 11. GLOBAL DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY EXON SKIPPING, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 12. GLOBAL DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY EXON SKIPPING, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 13. GLOBAL DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY GENE THERAPY, 2018-2024 (USD MILLION)
  • TABLE 14. GLOBAL DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY GENE THERAPY, 2025-2032 (USD MILLION)
  • TABLE 15. GLOBAL DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY GENE THERAPY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 16. GLOBAL DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY GENE THERAPY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 17. GLOBAL DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY GENE THERAPY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 18. GLOBAL DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY GENE THERAPY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 19. GLOBAL DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY GENE THERAPY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 20. GLOBAL DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY GENE THERAPY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 21. GLOBAL DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY AAV BASED, 2018-2024 (USD MILLION)
  • TABLE 22. GLOBAL DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY AAV BASED, 2025-2032 (USD MILLION)
  • TABLE 23. GLOBAL DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY AAV BASED, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 24. GLOBAL DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY AAV BASED, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 25. GLOBAL DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY AAV BASED, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 26. GLOBAL DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY AAV BASED, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 27. GLOBAL DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY AAV BASED, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 28. GLOBAL DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY AAV BASED, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 29. GLOBAL DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY SEROTYPE 6, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 30. GLOBAL DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY SEROTYPE 6, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 31. GLOBAL DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY SEROTYPE 6, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 32. GLOBAL DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY SEROTYPE 6, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 33. GLOBAL DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY SEROTYPE 6, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 34. GLOBAL DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY SEROTYPE 6, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 35. GLOBAL DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY SEROTYPE 9, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 36. GLOBAL DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY SEROTYPE 9, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 37. GLOBAL DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY SEROTYPE 9, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 38. GLOBAL DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY SEROTYPE 9, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 39. GLOBAL DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY SEROTYPE 9, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 40. GLOBAL DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY SEROTYPE 9, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 41. GLOBAL DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY NONVIRAL, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 42. GLOBAL DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY NONVIRAL, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 43. GLOBAL DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY NONVIRAL, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 44. GLOBAL DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY NONVIRAL, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 45. GLOBAL DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY NONVIRAL, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 46. GLOBAL DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY NONVIRAL, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 47. GLOBAL DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY STEROID THERAPY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 48. GLOBAL DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY STEROID THERAPY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 49. GLOBAL DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY STEROID THERAPY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 50. GLOBAL DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY STEROID THERAPY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 51. GLOBAL DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY STEROID THERAPY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 52. GLOBAL DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY STEROID THERAPY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 53. GLOBAL DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 54. GLOBAL DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 55. GLOBAL DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 56. GLOBAL DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 57. GLOBAL DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY HOSPITAL PHARMACIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 58. GLOBAL DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY HOSPITAL PHARMACIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 59. GLOBAL DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY HOSPITAL PHARMACIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 60. GLOBAL DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY HOSPITAL PHARMACIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 61. GLOBAL DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 62. GLOBAL DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 63. GLOBAL DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY ONLINE PHARMACIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 64. GLOBAL DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY ONLINE PHARMACIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 65. GLOBAL DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY ONLINE PHARMACIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 66. GLOBAL DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY ONLINE PHARMACIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 67. GLOBAL DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 68. GLOBAL DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 69. GLOBAL DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY RETAIL PHARMACIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 70. GLOBAL DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY RETAIL PHARMACIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 71. GLOBAL DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY RETAIL PHARMACIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 72. GLOBAL DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY RETAIL PHARMACIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 73. GLOBAL DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 74. GLOBAL DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 75. GLOBAL DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY HOME HEALTHCARE SETTINGS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 76. GLOBAL DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY HOME HEALTHCARE SETTINGS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 77. GLOBAL DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY HOME HEALTHCARE SETTINGS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 78. GLOBAL DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY HOME HEALTHCARE SETTINGS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 79. GLOBAL DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY HOME HEALTHCARE SETTINGS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 80. GLOBAL DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY HOME HEALTHCARE SETTINGS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 81. GLOBAL DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 82. GLOBAL DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY HOSPITALS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 83. GLOBAL DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 84. GLOBAL DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY HOSPITALS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 85. GLOBAL DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 86. GLOBAL DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 87. GLOBAL DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 88. GLOBAL DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 89. GLOBAL DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY SPECIALTY CLINICS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 90. GLOBAL DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY SPECIALTY CLINICS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 91. GLOBAL DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY SPECIALTY CLINICS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 92. GLOBAL DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY SPECIALTY CLINICS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 93. GLOBAL DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY FORM, 2018-2024 (USD MILLION)
  • TABLE 94. GLOBAL DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY FORM, 2025-2032 (USD MILLION)
  • TABLE 95. GLOBAL DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY CAPSULE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 96. GLOBAL DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY CAPSULE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 97. GLOBAL DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY CAPSULE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 98. GLOBAL DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY CAPSULE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 99. GLOBAL DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY CAPSULE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 100. GLOBAL DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY CAPSULE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 101. GLOBAL DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY INJECTABLE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 102. GLOBAL DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY INJECTABLE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 103. GLOBAL DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY INJECTABLE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 104. GLOBAL DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY INJECTABLE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 105. GLOBAL DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY INJECTABLE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 106. GLOBAL DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY INJECTABLE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 107. GLOBAL DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY ORAL TABLET, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 108. GLOBAL DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY ORAL TABLET, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 109. GLOBAL DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY ORAL TABLET, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 110. GLOBAL DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY ORAL TABLET, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 111. GLOBAL DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY ORAL TABLET, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 112. GLOBAL DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY ORAL TABLET, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 113. GLOBAL DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 114. GLOBAL DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 115. GLOBAL DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY INTRAMUSCULAR, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 116. GLOBAL DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY INTRAMUSCULAR, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 117. GLOBAL DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY INTRAMUSCULAR, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 118. GLOBAL DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY INTRAMUSCULAR, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 119. GLOBAL DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY INTRAMUSCULAR, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 120. GLOBAL DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY INTRAMUSCULAR, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 121. GLOBAL DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY INTRAVENOUS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 122. GLOBAL DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY INTRAVENOUS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 123. GLOBAL DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY INTRAVENOUS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 124. GLOBAL DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY INTRAVENOUS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 125. GLOBAL DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY INTRAVENOUS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 126. GLOBAL DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY INTRAVENOUS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 127. GLOBAL DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY ORAL, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 128. GLOBAL DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY ORAL, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 129. GLOBAL DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY ORAL, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 130. GLOBAL DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY ORAL, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 131. GLOBAL DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY ORAL, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 132. GLOBAL DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY ORAL, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 133. GLOBAL DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 134. GLOBAL DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 135. AMERICAS DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 136. AMERICAS DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 137. AMERICAS DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
  • TABLE 138. AMERICAS DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY DRUG CLASS, 2025-2032 (USD MILLION)
  • TABLE 139. AMERICAS DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY GENE THERAPY, 2018-2024 (USD MILLION)
  • TABLE 140. AMERICAS DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY GENE THERAPY, 2025-2032 (USD MILLION)
  • TABLE 141. AMERICAS DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY AAV BASED, 2018-2024 (USD MILLION)
  • TABLE 142. AMERICAS DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY AAV BASED, 2025-2032 (USD MILLION)
  • TABLE 143. AMERICAS DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 144. AMERICAS DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 145. AMERICAS DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 146. AMERICAS DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 147. AMERICAS DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY FORM, 2018-2024 (USD MILLION)
  • TABLE 148. AMERICAS DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY FORM, 2025-2032 (USD MILLION)
  • TABLE 149. AMERICAS DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 150. AMERICAS DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 151. NORTH AMERICA DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 152. NORTH AMERICA DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 153. NORTH AMERICA DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
  • TABLE 154. NORTH AMERICA DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY DRUG CLASS, 2025-2032 (USD MILLION)
  • TABLE 155. NORTH AMERICA DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY GENE THERAPY, 2018-2024 (USD MILLION)
  • TABLE 156. NORTH AMERICA DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY GENE THERAPY, 2025-2032 (USD MILLION)
  • TABLE 157. NORTH AMERICA DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY AAV BASED, 2018-2024 (USD MILLION)
  • TABLE 158. NORTH AMERICA DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY AAV BASED, 2025-2032 (USD MILLION)
  • TABLE 159. NORTH AMERICA DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 160. NORTH AMERICA DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 161. NORTH AMERICA DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 162. NORTH AMERICA DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 163. NORTH AMERICA DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY FORM, 2018-2024 (USD MILLION)
  • TABLE 164. NORTH AMERICA DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY FORM, 2025-2032 (USD MILLION)
  • TABLE 165. NORTH AMERICA DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 166. NORTH AMERICA DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 167. LATIN AMERICA DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 168. LATIN AMERICA DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 169. LATIN AMERICA DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
  • TABLE 170. LATIN AMERICA DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY DRUG CLASS, 2025-2032 (USD MILLION)
  • TABLE 171. LATIN AMERICA DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY GENE THERAPY, 2018-2024 (USD MILLION)
  • TABLE 172. LATIN AMERICA DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY GENE THERAPY, 2025-2032 (USD MILLION)
  • TABLE 173. LATIN AMERICA DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY AAV BASED, 2018-2024 (USD MILLION)
  • TABLE 174. LATIN AMERICA DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY AAV BASED, 2025-2032 (USD MILLION)
  • TABLE 175. LATIN AMERICA DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 176. LATIN AMERICA DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 177. LATIN AMERICA DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 178. LATIN AMERICA DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 179. LATIN AMERICA DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY FORM, 2018-2024 (USD MILLION)
  • TABLE 180. LATIN AMERICA DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY FORM, 2025-2032 (USD MILLION)
  • TABLE 181. LATIN AMERICA DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 182. LATIN AMERICA DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 183. EUROPE, MIDDLE EAST & AFRICA DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 184. EUROPE, MIDDLE EAST & AFRICA DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 185. EUROPE, MIDDLE EAST & AFRICA DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
  • TABLE 186. EUROPE, MIDDLE EAST & AFRICA DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY DRUG CLASS, 2025-2032 (USD MILLION)
  • TABLE 187. EUROPE, MIDDLE EAST & AFRICA DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY GENE THERAPY, 2018-2024 (USD MILLION)
  • TABLE 188. EUROPE, MIDDLE EAST & AFRICA DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY GENE THERAPY, 2025-2032 (USD MILLION)
  • TABLE 189. EUROPE, MIDDLE EAST & AFRICA DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY AAV BASED, 2018-2024 (USD MILLION)
  • TABLE 190. EUROPE, MIDDLE EAST & AFRICA DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY AAV BASED, 2025-2032 (USD MILLION)
  • TABLE 191. EUROPE, MIDDLE EAST & AFRICA DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 192. EUROPE, MIDDLE EAST & AFRICA DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 193. EUROPE, MIDDLE EAST & AFRICA DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 194. EUROPE, MIDDLE EAST & AFRICA DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 195. EUROPE, MIDDLE EAST & AFRICA DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY FORM, 2018-2024 (USD MILLION)
  • TABLE 196. EUROPE, MIDDLE EAST & AFRICA DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY FORM, 2025-2032 (USD MILLION)
  • TABLE 197. EUROPE, MIDDLE EAST & AFRICA DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 198. EUROPE, MIDDLE EAST & AFRICA DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 199. EUROPE DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 200. EUROPE DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 201. EUROPE DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
  • TABLE 202. EUROPE DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY DRUG CLASS, 2025-2032 (USD MILLION)
  • TABLE 203. EUROPE DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY GENE THERAPY, 2018-2024 (USD MILLION)
  • TABLE 204. EUROPE DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY GENE THERAPY, 2025-2032 (USD MILLION)
  • TABLE 205. EUROPE DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY AAV BASED, 2018-2024 (USD MILLION)
  • TABLE 206. EUROPE DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY AAV BASED, 2025-2032 (USD MILLION)
  • TABLE 207. EUROPE DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 208. EUROPE DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 209. EUROPE DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 210. EUROPE DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 211. EUROPE DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY FORM, 2018-2024 (USD MILLION)
  • TABLE 212. EUROPE DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY FORM, 2025-2032 (USD MILLION)
  • TABLE 213. EUROPE DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 214. EUROPE DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 215. MIDDLE EAST DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 216. MIDDLE EAST DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 217. MIDDLE EAST DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
  • TABLE 218. MIDDLE EAST DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY DRUG CLASS, 2025-2032 (USD MILLION)
  • TABLE 219. MIDDLE EAST DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY GENE THERAPY, 2018-2024 (USD MILLION)
  • TABLE 220. MIDDLE EAST DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY GENE THERAPY, 2025-2032 (USD MILLION)
  • TABLE 221. MIDDLE EAST DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY AAV BASED, 2018-2024 (USD MILLION)
  • TABLE 222. MIDDLE EAST DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY AAV BASED, 2025-2032 (USD MILLION)
  • TABLE 223. MIDDLE EAST DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 224. MIDDLE EAST DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 225. MIDDLE EAST DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 226. MIDDLE EAST DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 227. MIDDLE EAST DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY FORM, 2018-2024 (USD MILLION)
  • TABLE 228. MIDDLE EAST DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY FORM, 2025-2032 (USD MILLION)
  • TABLE 229. MIDDLE EAST DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 230. MIDDLE EAST DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 231. AFRICA DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 232. AFRICA DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 233. AFRICA DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
  • TABLE 234. AFRICA DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY DRUG CLASS, 2025-2032 (USD MILLION)
  • TABLE 235. AFRICA DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY GENE THERAPY, 2018-2024 (USD MILLION)
  • TABLE 236. AFRICA DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY GENE THERAPY, 2025-2032 (USD MILLION)
  • TABLE 237. AFRICA DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY AAV BASED, 2018-2024 (USD MILLION)
  • TABLE 238. AFRICA DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY AAV BASED, 2025-2032 (USD MILLION)
  • TABLE 239. AFRICA DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 240. AFRICA DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 241. AFRICA DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 242. AFRICA DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 243. AFRICA DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY FORM, 2018-2024 (USD MILLION)
  • TABLE 244. AFRICA DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY FORM, 2025-2032 (USD MILLION)
  • TABLE 245. AFRICA DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 246. AFRICA DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 247. ASIA-PACIFIC DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 248. ASIA-PACIFIC DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 249. ASIA-PACIFIC DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
  • TABLE 250. ASIA-PACIFIC DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY DRUG CLASS, 2025-2032 (USD MILLION)
  • TABLE 251. ASIA-PACIFIC DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY GENE THERAPY, 2018-2024 (USD MILLION)
  • TABLE 252. ASIA-PACIFIC DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY GENE THERAPY, 2025-2032 (USD MILLION)
  • TABLE 253. ASIA-PACIFIC DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY AAV BASED, 2018-2024 (USD MILLION)
  • TABLE 254. ASIA-PACIFIC DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY AAV BASED, 2025-2032 (USD MILLION)
  • TABLE 255. ASIA-PACIFIC DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 256. ASIA-PACIFIC DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 257. ASIA-PACIFIC DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 258. ASIA-PACIFIC DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 259. ASIA-PACIFIC DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY FORM, 2018-2024 (USD MILLION)
  • TABLE 260. ASIA-PACIFIC DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY FORM, 2025-2032 (USD MILLION)
  • TABLE 261. ASIA-PACIFIC DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 262. ASIA-PACIFIC DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 263. GLOBAL DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 264. GLOBAL DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 265. ASEAN DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 266. ASEAN DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 267. ASEAN DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
  • TABLE 268. ASEAN DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY DRUG CLASS, 2025-2032 (USD MILLION)
  • TABLE 269. ASEAN DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY GENE THERAPY, 2018-2024 (USD MILLION)
  • TABLE 270. ASEAN DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY GENE THERAPY, 2025-2032 (USD MILLION)
  • TABLE 271. ASEAN DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY AAV BASED, 2018-2024 (USD MILLION)
  • TABLE 272. ASEAN DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY AAV BASED, 2025-2032 (USD MILLION)
  • TABLE 273. ASEAN DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 274. ASEAN DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 275. ASEAN DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 276. ASEAN DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 277. ASEAN DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY FORM, 2018-2024 (USD MILLION)
  • TABLE 278. ASEAN DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY FORM, 2025-2032 (USD MILLION)
  • TABLE 279. ASEAN DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 280. ASEAN DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 281. GCC DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 282. GCC DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 283. GCC DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
  • TABLE 284. GCC DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY DRUG CLASS, 2025-2032 (USD MILLION)
  • TABLE 285. GCC DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY GENE THERAPY, 2018-2024 (USD MILLION)
  • TABLE 286. GCC DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY GENE THERAPY, 2025-2032 (USD MILLION)
  • TABLE 287. GCC DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY AAV BASED, 2018-2024 (USD MILLION)
  • TABLE 288. GCC DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY AAV BASED, 2025-2032 (USD MILLION)
  • TABLE 289. GCC DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 290. GCC DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 291. GCC DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 292. GCC DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 293. GCC DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY FORM, 2018-2024